Physician profile
Joseph J Boyd
NPI 1922045137
$1,511.26
in general payments reported to CMS, 2019-2025
19 companies · $162 in 2025
The $162 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $291 · 2020: $70.82 · 2021: $104 · 2023: $499 · 2024: $385 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,046.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $316.82 | 2019-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $197.91 | 2019-2025 | Avvigo Guidance System |
| Novartis Pharmaceuticals Corporation | $172.89 | 2019-2024 | |
| Penumbra, INC. | $147.22 | 2023 | Indigo System |
| Astrazeneca Pharmaceuticals LP | $118.82 | 2019-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $107.01 | 2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $101.64 | 2019-2024 | Eliquis |
| Pfizer INC. | $59.22 | 2021-2024 | |
| Inspire Medical Systems, INC. | $42.23 | 2023 | Inspire |
| Janssen Pharmaceuticals, INC | $41.80 | 2023 | Xarelto |
| Regeneron Healthcare Solutions, INC. | $39.37 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $37.27 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $31.91 | 2023 | Arcalyst |
| Sanofi-Aventis U.S. LLC | $20.31 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $19.36 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $17.80 | 2024 | |
| Novo Nordisk INC | $16.23 | 2023 | Rybelsus, Ozempic |
| Scilex Pharmaceuticals INC. | $13.45 | 2021 | |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Boyd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.